The p-i concept: Evidence and implications

Drug Hypersensitivity

Volumn , Issue , 2007, Pages 66-73

  Gerber Dr , Basil O ^a   Pichler, Werner J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349721029     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000104190     Document Type: Chapter

References (48)

1. Landsteiner K, Jacobs J: Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935; 61: 643-656.
2. Naisbitt DJ, Williams DP, Pirmohamed M, Kitteringham NR, Park BK: Reactive metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol 2001; 1: 317-325.
3. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK: Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drugspecific T cell clones. Mol Pharmacol 2003; 63: 732-741.
4. Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, Berry N, Stachulski AV, Clarke SE, Pichler WJ, Pirmohamed M, Park BK, Naisbitt DJ: Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006; 118: 233-241.
5. Zanni MP, Mauri-Hellweg D, Brander C, Wendland T, Schnyder B, Frei E, von Greyerz S, Bircher A, Pichler WJ: Characterization of lidocaine-specific T cells. J Immunol 1997; 158: 1139-1148.
6. Zanni MP, von Greyerz S, Hari Y, Schnyder B, Pichler WJ: Recognition of local anesthetics by αβ+ T cells. J Invest Dermatol 1999; 112: 197-204.
7. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK: Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003;11: 1393-1403.
8. Schmid DA, Depta JP, Pichler WJ: T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin Exp Allergy 2006; 36: 59-69.
9. Schmid DA, Depta JP, Luthi M, Pichler WJ: Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds. Mol Pharmacol 2006; 70: 356-365.
10. Sieben S, Kawakubo Y, Al Masaoudi T, Merk HF, Blomeke B: Delayed-type hypersensitivity reaction to p -phenylenediamine is mediated by two different pathways of antigen recognition by specific αβ human T-cell clones. J Allergy Clin Immunol 2002; 109: 1005-1011.
11. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ: Direct, MHCdependent presentation of the drug sulfamethoxazole to human αβ T cell clones. J Clin Invest 1997; 100: 136-141.
12. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, Valitutti S, Pichler WJ: HLA-restricted, processing-and metabolism-independent pathway of drug recognition by human αβ T lymphocytes. J Clin Invest 1998;102: 1591-1598.
13. Depta JP, Altznauer F, Gamerdinger K, Burkhart C, Weltzien HU, Pichler WJ: Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J Allergy Clin Immunol 2004; 113: 519-527.
14. Cribb AE, Spielberg SP: Sulfamethoxazole is metabolized to the hydroxylaminein humans. Clin Pharmacol Ther 1992; 51: 522-526.
15. Naisbitt DJ, Vilar FJ, Stalford AC, Wilkins EG, Pirmohamed M, Park BK: Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res Hum Retroviruses 2000; 16: 1929-1938.
16. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, Park BK, Pichler WJ: Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000; 164: 6647-6654.
17. Burkhart C, von Greyerz S, Depta JP,Naisbitt DJ, Britschgi M, Park KB, Pichler WJ: Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 2001; 132: 623-630.
18. Pichler WJ: Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2:301-305.
19. Gerber BO, Pichler WJ: Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol 2004;16: 732-737
20. Gerber BO, Pichler WJ: Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions. AAPS J 2006; 8:E160-165.
21. Von Greyerz S, Bultemann G, Schnyder K, Burkhart C, Lotti B, Hari Y, Pichler WJ: Degeneracy and additional alloreactivity of drug-specific human αβ( +) T cell clones. Int Immunol 2001; 13: 877-885.
22. Beeley NR: Can peptides be mimicked? Drug Discov Today 2000; 5: 354-363. 23 Lu L, Vollmer J, Moulon C, Weltzien HU, Marrack P, Kappler J: Components of the ligand for a Ni ++ reactive human T cell clone. J Exp Med 2003; 197: 567-574.
23. Lu L, Vollmer J, Moulon C, Weltzien HU, Marrack P, Kappler J: Components of the ligand for a Ni ++ reactive human T cell clone. J Exp Med 2003; 197: 567-574.
24. Vollmer J, Weltzien HU, Gamerdinger K, Lang S, Choleva Y, Moulon C: Antigen contacts by Ni-reactive TCR: typical αβ chain cooperation versus α chain-dominated specificity. Int Immunol 2000; 12: 1723-1731.
25. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT: Association between presence of HLA-B*5701,HLA-DR7,and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
26. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180-4185.
27. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.
28. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-4139.
29. Gamerdinger K, Moulon C, Karp DR, Van Bergen J, Koning F, Wild D, Pflugfelder U, Weltzien HU: A new type of metal recognition by human T cells: contact residues for peptide-independent bridging of T cell receptor and major histocompatibility complex by nickel. J Exp Med 2003; 197: 1345-1353.
30. Rao A, Ko WW, Faas SJ, Cantor H:Binding of antigen in the absence of histocompatibility proteins by arsonate-reactive T-cell clones. Cell 1984; 36: 879-888.
31. Rao A, Faas SJ, Cantor H: Analogs that compete for antigen binding to an arsonate-reactive T-cell clone inhibit the functional response to arsonate. Cell 1984; 36: 889-895.
32. Diamond DJ, Szalay P, Symer D, Hao P, Shin HS, Dintzis RZ, Dintzis HM, Reinherz EL, Siliciano RF: Major histocompatibility complex independent T cell receptor-antigen interaction: functional analysis using fluorescein derivatives. J Exp Med 1991; 174: 229-241.
33. Stockl J, Majdic O, Fischer G, Maurer D, Knapp W: Monomorphic molecules function as additional recognition structures on haptenated target cells for HLA-A1-restricted, hapten-specific CTL. J Immunol 2001; 167: 2724-2733.
34. Thierse HJ, Gamerdinger K, Junkes C, Guerreiro N, Weltzien HU: T cell receptor interaction with haptens: metal ions as non-classical haptens. Toxicology 2005; 209: 101-107.
35. Janeway CA Jr: The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13: 11-16.
36. Seguin B, Uetrecht J: The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003; 3: 235-242.
37. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
38. Aiba S, Manome H, Nakagawa S, Mollah ZU, Mizuashi M, Ohtani T, Yoshino Y, Tagami H: p38 mitogen-activated protein kinase and extracellular signalregulated kinases play distinct roles in the activation of dendritic cells by two representative haptens, NiCl2 and 2,4-dinitrochlorobenzene. J Invest Dermatol 2003; 120: 390-399.
39. Bruchhausen S, Zahn S, Valk E, Knop J, Becker D: Thiol antioxidants block theactivation of antigen-presenting cells by contact sensitizers. J Invest Dermatol 2003; 121: 1039-1044.
40. Becker D, Valk E, Zahn S, Brand P, Knop J: Coupling of contact sensitizers to thiol groups is a key event for the activation of monocytes and monocyte-derived dendritic cells. J Invest Dermatol 2003; 120: 233-238.
41. Hulette BC, Ryan CA, Gildea LA, Gerberick GF: Relationship of CD86 surface marker expression and cytotoxicity on dendritic cells exposed to chemical allergen. Toxicol Appl Pharmacol 2005; 209: 159-166.
42. Christiansen C, Pichler WJ, Skotland T: Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations. Eur Radiol 2000; 10:1965-1975.
43. Christiansen C: Late-onset allergy-like reactions to X-ray contrast media. Curr Opin Allergy Clin Immunol 2002; 2:333-339.
44. Christiansen C: X-ray contrast media -an overview. Toxicology 2005; 209: 185-187.
45. Amrani A, Serra P, Yamanouchi J, Trudeau JD, Tan R, Elliott JF, Santamaria P: Expansion of the antigenic repertoire of a single T cell receptor upon T cell activation. J Immunol 2001; 167:655-666.
46. Engler OB, Strasser I, Naisbitt DJ, Cerny A, Pichler WJ: A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology 2004; 197:47-56
47. Pirmohamed M, Park BK: HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001; 1: 311-316.
48. Lerch M, Pichler WJ: The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol 2004; 4: 411-419.